Comparison between the two drug regimens for the treatment of H.pylory infection

Comparison between the two drug regimens of "Amoxicillin-Rifaximin-PPI" and "Amoxicillin-Clarithromycin-PPI" for the treatment of H.pylory infection

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230902059322N1

Enrollment

Registered

2023-11-02

Start date

2023-09-06

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori [H. pylori]. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: A 14-day four-drug regimen containing rifaximin (rifaximin 500 mg, amoxicillin 1 g, Pantoprazole 40 mg and bismuth tablets, all twice a day). Intervention 2: Contro

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Proof of H. pylori infection by rapid urease test or histological evaluation of gastric antrum and corpus callosum samples by Giemsa staining Informed consent of the patient

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Eradication of H. pylori, evaluated by urine stool antigen test. Timepoint: 8 weeks after the end of treatment. Method of measurement: urine stool antigen test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Vaez Mousavi

Tabriz University of Medical Sciences

vaezmousavi@tbzmed.ac.ir+98 41 3551 4025

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026